Menu

Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript
📰

Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript

All Articles on Seeking Alpha·10 days ago
#A9Yl1JlV
Reading 0:00
15s threshold

Evommune, Inc. ( EVMN ) Discusses In Licensing of EVO570 for Autoimmune Diseases November 5, 2026 8:30 AM EST

Company Participants

Luis Peña - Founder, President, CEO & Director

Gregory Moss - Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer

Jeegar Patel - Chief Scientific Officer

J. Jackson - Senior Vice President of Clinical Development

Presentation

Luis Peña

Founder, President, CEO & Director

Good morning, and thank you for joining us. I'm Luis Pena, the President and CEO of Evommune. Yesterday, we announced our agreement with Hinova for global development rights, excluding Greater China to EVO570, an oral VAV1 molecular glue degrader. Over the next few minutes, we'll explain why we did this deal, what the science shows and how EVO570 fits into the rest of our portfolio. I'm joined today by Greg Moss, our Chief Business and Legal Officer, who will cover the deal terms and the competitive landscape.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.